MedTrace Logo

US Ovulation Inhibition Study in Obese Women

NCT00873483 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2021-04-08

No results posted yet for this study

Summary

Birth Control Patch Study

Conditions

  • Contraception

Interventions

DRUG

Ethinylestradiol/Gestodene (BAY86-5016)

0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-03-03
Completion
2010-03-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00873483 on ClinicalTrials.gov